Cogent Advances Bezuclastinib Toward FDA Filing Following Positive Phase II Mastocytosis Results
SHERIDAN, WYOMING – July 8, 2025 – Cogent Biosciences is accelerating its strategic trajectory with plans to submit its first New Drug Application (NDA) to the FDA by year-end, following strong Phase II data for its investigational tyrosine kinase inhibitor, bezuclastinib. The move positions Cogent as a serious contender in the systemic mastocytosis treatment landscape, directly challenging Blueprint Medicines' market presence.
Strategic Differentiation in a Competitive Field